Johannes Roedl

Concepts (94)

Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.


Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Esophageal Neoplasms
7
2009
98
2.390
Why?
Tomography, X-Ray Computed
8
2017
673
2.280
Why?
Positron-Emission Tomography
5
2009
161
1.330
Why?
Glaucoma, Open-Angle
5
2008
8
1.290
Why?
Adenocarcinoma
3
2009
389
0.980
Why?
Homocysteine
3
2008
10
0.850
Why?
Exfoliation Syndrome
4
2007
4
0.840
Why?
Tomography, Emission-Computed
2
2009
48
0.830
Why?
Fluorodeoxyglucose F18
5
2009
74
0.800
Why?
Image-Guided Biopsy
1
2017
9
0.780
Why?
Needles
1
2017
21
0.770
Why?
Tears
2
2008
17
0.760
Why?
Radiation Dosage
1
2017
64
0.750
Why?
Biopsy, Fine-Needle
1
2017
68
0.740
Why?
Carcinoma, Squamous Cell
2
2008
223
0.680
Why?
Aged
12
2009
4472
0.550
Why?
Sensitivity and Specificity
5
2009
555
0.450
Why?
Male
13
2009
8838
0.450
Why?
Aqueous Humor
2
2006
4
0.440
Why?
Female
13
2009
9489
0.440
Why?
Lymphatic Metastasis
1
2009
172
0.410
Why?
Esophageal Diseases
1
2008
1
0.410
Why?
Subtraction Technique
1
2008
5
0.410
Why?
Radiopharmaceuticals
4
2009
154
0.390
Why?
Survival Analysis
1
2009
385
0.390
Why?
Carcinoma
1
2009
141
0.380
Why?
Neoplasm Staging
4
2009
476
0.370
Why?
Hyperhomocysteinemia
1
2007
3
0.370
Why?
Vitamin B Deficiency
1
2007
4
0.370
Why?
Glaucoma
1
2007
9
0.370
Why?
Eye
1
2007
25
0.370
Why?
Hydrolases
1
2006
3
0.360
Why?
Risk Assessment
1
2009
540
0.350
Why?
Neoplasm Recurrence, Local
1
2008
312
0.350
Why?
Humans
13
2009
18498
0.310
Why?
Neoadjuvant Therapy
3
2008
113
0.290
Why?
Predictive Value of Tests
3
2009
451
0.280
Why?
Combined Modality Therapy
3
2008
346
0.280
Why?
Chromatography, High Pressure Liquid
3
2008
71
0.280
Why?
Risk Factors
4
2009
1115
0.240
Why?
Middle Aged
5
2008
5845
0.240
Why?
Case-Control Studies
4
2008
342
0.210
Why?
Esophagectomy
2
2008
20
0.210
Why?
Area Under Curve
2
2008
59
0.200
Why?
Tumor Burden
2
2008
61
0.200
Why?
Survival Rate
2
2009
391
0.200
Why?
Prospective Studies
4
2008
855
0.190
Why?
Equipment Design
1
2017
168
0.190
Why?
Vitamin B 12
2
2007
13
0.180
Why?
Reproducibility of Results
2
2009
567
0.180
Why?
Treatment Outcome
2
2008
2076
0.130
Why?
Massachusetts
1
2009
6
0.110
Why?
Esophagogastric Junction
1
2009
14
0.110
Why?
Esophagitis
1
2008
15
0.100
Why?
Vitamin B Complex
1
2008
7
0.100
Why?
ROC Curve
1
2008
98
0.100
Why?
Chemotherapy, Adjuvant
1
2008
120
0.100
Why?
Radiotherapy, Adjuvant
1
2008
115
0.100
Why?
Chi-Square Distribution
1
2008
121
0.100
Why?
Precancerous Conditions
1
2008
57
0.100
Why?
Cisplatin
1
2008
76
0.100
Why?
Postoperative Care
1
2008
57
0.100
Why?
Regression Analysis
1
2008
149
0.100
Why?
Kaplan-Meier Estimate
1
2008
171
0.100
Why?
Proportional Hazards Models
1
2008
194
0.100
Why?
Dry Eye Syndromes
1
2008
10
0.100
Why?
Feasibility Studies
1
2008
167
0.100
Why?
Preoperative Care
1
2008
105
0.100
Why?
Incidence
1
2009
360
0.100
Why?
Disease-Free Survival
1
2008
297
0.100
Why?
Imaging, Three-Dimensional
1
2009
144
0.100
Why?
Patient Selection
1
2008
155
0.100
Why?
Vitamin B 6 Deficiency
1
2007
1
0.090
Why?
Plasma
1
2007
12
0.090
Why?
Folic Acid Deficiency
1
2007
4
0.090
Why?
Vitamin B 12 Deficiency
1
2007
7
0.090
Why?
Vitamin B 6
1
2006
1
0.090
Why?
Diagnosis, Differential
1
2008
462
0.090
Why?
Cohort Studies
1
2008
585
0.090
Why?
Folic Acid
1
2006
19
0.090
Why?
Prognosis
1
2009
798
0.090
Why?
Methylenetetrahydrofolate Reductase (NADPH2)
1
2005
5
0.080
Why?
Antineoplastic Agents
1
2008
490
0.080
Why?
Polymorphism, Single Nucleotide
1
2005
161
0.070
Why?
Aged, 80 and over
1
2008
1795
0.070
Why?
Genetic Predisposition to Disease
1
2005
245
0.070
Why?
Retrospective Studies
1
2008
1787
0.070
Why?
Intraocular Pressure
1
2005
11
0.020
Why?
Cataract
1
2005
14
0.020
Why?
Gene Frequency
1
2005
47
0.020
Why?
Odds Ratio
1
2005
148
0.020
Why?
Blood-Aqueous Barrier
1
2004
1
0.020
Why?
Prevalence
1
2005
237
0.020
Why?
Enzyme-Linked Immunosorbent Assay
1
2004
148
0.020
Why?
Roedl's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (94)
Explore
_
Co-Authors (6)
Explore
_
Similar People (60)
Explore
_
Same Department Expand Description
Explore
_